Are you Dr. Thirman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 80 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 888-824-0200Fax+1 773-702-0963
Summary
- Dr. Michael Thirman, MD is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois and Minnesota. He is affiliated with University of Chicago Medical Center and is an Associate Professor of Medicine at University of Chicago Medicine.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1990 - 1994
University of MinnesotaResidency, Internal Medicine, 1986 - 1989
University of Michigan Medical SchoolClass of 1986
Certifications & Licensure
IL State Medical License 1990 - 2026
MN State Medical License 1989 - 1990- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
- Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsMenin Inhibition With Revumenib for-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano
Journal of Clinical Oncology. 2025-01-01 - 6 citationsGenetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, Andrew H Wei, Brian A Jonas
Blood. 2024-11-21 - Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T Nawas
Leukemia & Lymphoma. 2024-06-01
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Join now to see all
Press Mentions
203 UChicago Medicine Doctors Named to 2022 Top Docs ListJanuary 21st, 2022
Long-Sought Genetic Model of Common Infant Leukemia DescribedNovember 10th, 2016
Grant Support
- Mll-Fusions And Cooperating Mutations In Acute LeukemiaNational Cancer Institute2005–2009
- MLL Fusions And Cooperating Mutations In Acute LeukemiaNational Cancer Institute2004–2008
- Genetic Analysis Of The MLL-ELL Fusion ProteinNational Cancer Institute1999–2003
